ATRN 1051
Alternative Names: APR-1051; ATRN-1051; ATRN-W1051Latest Information Update: 10 Jun 2024
At a glance
- Originator Atrin Pharmaceuticals
- Developer Aprea Therapeutics; Atrin Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 28 May 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06260514) .
- 10 Apr 2024 Pharmacodynamics data from a preclinical study in Cancer released by Aprea Therapeutics
- 11 Mar 2024 Aprea Therapeutics plans the phase I ACESOT-1051 trial for Cancer (Monotherapy, Late-stage disease, Metastatic disease) in the 1H of 2024 (NCT06260514)